This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
F13A1 / Coagulation factor XIII A chain · Western blot design guide
Design a Western Blot for F13A1
Source-linked F13A1 Western blot protocol options, expected-band and isoform facts, troubleshooting for weak or shifted signal, and recommended anti-F13A1 WB antibodies. Everything you need to plan the experiment before you commit precious samples.
Evidence assembled September 2026 · For research use; verify linked source records and product datasheet before use
F13A1 Western Blot Experimental Design Guide
Expected bands, source-linked protocol options, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | ~83.3 kDa | |
| Observed band | ~83 kDa | |
| Gel | 10% (catalog M02047-1) | |
| Positive control | Skin (IHC candidate; verify WB) +2 more | |
| Negative control | Adrenal gland (IHC candidate; verify WB) |
Important caveats
Reasons your observed band may differ from the expected size.
| PTM | Glycosylated + Acetylated | |
| Caveat | Cleavage-state controls | |
| Gene-set association | MSigDB Hallmark membership | |
| Isoform | 1 isoform(s) |
Section 1
Source-Linked F13A1 Western Blot Protocol Options
The M02047-1 protocol combines labelled catalog values with standard starting conditions. Published comparisons retain their own sample, reagent and detection scope.
| Sample / lysate | human placenta, human THP-1 (catalog M02047-1) |
| Gel % | 10% (catalog M02047-1) |
| Load | 30 ug; reducing conditions (catalog M02047-1) |
| Transfer | a nitrocellulose membrane at 150 mA for 50-90 minutes (catalog M02047-1) |
| Membrane | nitrocellulose membrane (catalog M02047-1) |
| Blocking | 5% non-fat milk/TBS for 1.5 hour at RT (catalog M02047-1) |
| Primary antibody | M02047-1 · 1:500 (catalog M02047-1) |
| Primary incubation | overnight at 4°C (catalog M02047-1) |
| Secondary antibody | goat anti-rabbit IgG-HRP, 1:5000 (catalog M02047-1) |
| Secondary incubation | 1.5 hour at RT (catalog M02047-1) |
| Wash | TBS-0.1%Tween 3 times with 5 minutes each (catalog M02047-1) |
| Detection | ECL (catalog M02047-1) |
Section 2
What Is the Expected F13A1 Western Blot Band Size?
F13A1 is predicted at 83.3 kDa and observed at ~83 kDa; the small difference has no established cause.
| Dominant band at ~83 kDa | Matches the empirical F13A1 band and its 83.3 kDa predicted mass |
| Band below ~83 kDa | May reflect removal of the residue 2–38 propeptide; confirm its identity |
| Band near ~83 kDa without a clear shift | The Asn614 N-linked glycosylation site alone does not establish a visible mobility change |
| Faint or absent band in a whole-cell lysate | F13A1 is secreted into plasma as well as present in the cytoplasm |
💡Expected F13A1 appearanceF13A1 has a predicted mass of 83.3 kDa and an empirical band at ~83 kDa under reducing conditions; confirm band identity with appropriate controls.
| Predicted F13A1 mass | 83.3 kDa provides the reference for the observed ~83 kDa band |
| Residue 2–38 propeptide | Cleavage could yield a smaller mature chain; its migration is not supplied |
| Asn614 N-linked glycosylation site | May affect migration, but a visible shift is not established |
| Two A chains in the A2B2 tetramer | Assembly increases native complex mass; a higher SDS-PAGE band is not established |
| Situation | Likely cause | Next action |
|---|---|---|
| No band in lysate | F13A1 may be secreted into plasma or scarce in the sampled cells | Check an appropriate positive lysate and plasma-containing sample |
| Band higher than expected | Asn614 glycosylation or complex retention is possible, but neither is established as the cause | Compare reducing conditions and verify identity with a positive control |
| Band lower than expected | Propeptide cleavage may reduce chain size | Compare precursor and processed samples with an antibody that recognizes both |
| Multiple bands | Precursor and processed F13A1 may coexist; other bands may be nonspecific | Compare processing conditions and use an independent F13A1 antibody |
| Weak or no signal | F13A1 abundance may be low in the selected sample | Check sample loading and a known positive control |
| Fragments below expected size | Sample proteolysis may generate smaller F13A1 fragments | Prepare samples promptly with protease inhibitors and compare a fresh sample |
Experiment evidence
Western blot images showing F13A1 band
M02047-1 · F13A1
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for F13A1 Western blot
🧪HPA-IHC candidate guidance (verify in WB): For positive controls for F13A1 in Western blot, you can use skin tissue, which has high HPA expression.
Positive control: Skin (IHC candidate; verify WB)
Negative control: Adrenal gland (IHC candidate; verify WB)
Loading controls: Run GAPDH, β-actin, and a total-protein stain such as Ponceau alongside the samples.
⚠️Feasibility: F13A1 is cytoplasmic but also secreted into plasma, so tissue lysate and plasma signals may differ.
HPA tissue expression evidence for F13A1
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Higher expression tissues · candidate positive controls from IHC
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Skin | fibrohistiocytic cells | High | Protein (IHC) | HPA → |
| Soft tissue | fibroblasts | High | Protein (IHC) | HPA → |
| Endometrium | cells in endometrial stroma | Medium | Protein (IHC) | HPA → |
Lower expression tissues · IHC evidence, not confirmed WB-negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adrenal gland | glandular cells | Not detected | Protein (IHC) | HPA → |
| Appendix | glandular cells | Not detected | Protein (IHC) | HPA → |
| Bone marrow | hematopoietic cells | Not detected | Protein (IHC) | HPA → |
| Breast | adipocytes | Not detected | Protein (IHC) | HPA → |
| Bronchus | respiratory epithelial cells | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced F13A1 Western Blot Tips
Deeper troubleshooting and optimisation questions for F13A1, answered from its protein features.
How should F13A1 band migration be interpreted?
Band shift · Use the separately labelled calculated mass and catalog-observed evidence above. A sequence annotation does not establish an observed migration shift. Verify target identity with orthogonal controls.
Do annotated F13A1 isoforms explain multiple bands?
Isoforms · Only one isoform is listed, with no alternative sequence supplied. Do not assign additional bands to annotated isoforms on this evidence alone; assess their identity separately.
Which modifications should I consider when interpreting F13A1 bands?
PTM · The supplied UniProt coordinates identify N-acetylserine at position 2 and an N-linked glycosylation site at Asn614. Position 2 lies within the annotated propeptide, 2..38. These are UniProt sequence coordinates; antibody or paper numbering may differ. Neither site alone demonstrates a visible band shift.
Does this guide establish induction of F13A1?
Induction · No general induction response is established by this guide. A pathway or gene-set association is not evidence of induction in a particular specimen. Verify the relevant treatment and control in a target-specific experiment.
What transfer method to use for F13A1 Western blot?
Transfer · Target efficient transfer around 83 kDa and check transfer with a total-protein stain. The supplied features do not specify a membrane, transfer method, or settings.
How should blocking be optimized?
Blocking · Standard workflow guidance: follow the M02047-1 datasheet where specified. Otherwise compare 5% milk or 5% BSA in TBST; for a phospho-specific assay start with BSA. Optimize background and specific signal with matched controls.
How should F13A1 be quantified?
Quantitation · Standard workflow guidance: quantify only a validated target band within the linear exposure range. Use consistent sample preparation and loading, retain biological replicates, and avoid interpreting saturation or loading differences as regulation.
Why is the F13A1 band near 83 kDa?
Interpretation · The predicted mass is 83.3 kDa, close to the observed band near 83 kDa. Use that region as a starting point for identification; the listed features do not establish an additional visible shift.
UniProt annotates a propeptide at positions 2..38. When interpreting a smaller band, consider processing, but this annotation alone does not establish that a distinct processed band will appear.
F13A1 is cytoplasmic in most tissues and is also secreted into blood plasma. Compare like sample fractions and normalize within each fraction; differences between cell lysate and plasma may reflect compartment as well as abundance.
F13A1 forms a tetramer with two A chains and two F13B chains. A high band warrants checking whether the sample preparation preserves complexes, but oligomer annotation alone cannot identify that band. The supplied features list no disulfide bonds.
UniProt annotates a propeptide at positions 2..38. When interpreting a smaller band, consider processing, but this annotation alone does not establish that a distinct processed band will appear.
F13A1 is cytoplasmic in most tissues and is also secreted into blood plasma. Compare like sample fractions and normalize within each fraction; differences between cell lysate and plasma may reflect compartment as well as abundance.
F13A1 forms a tetramer with two A chains and two F13B chains. A high band warrants checking whether the sample preparation preserves complexes, but oligomer annotation alone cannot identify that band. The supplied features list no disulfide bonds.
Boster reagents
F13A1 Western Blot Antibodies
Catalog antibodies with Western blot application and product-specific WB images. Evaluate suitability with the reported sample, controls and experimental conditions.
Real WB data
Anti-Factor XIIIa F13A1 Monoclonal Antibody
Cat # M02047-1
The catalog reports one anti-F13A1 antibody, M02047-1, for Western blotting. Its WB image shows an approximately 83 kDa band in human placenta and THP-1 lysates under reducing conditions. Rat WB performance is not shown in the supplied evidence.
Which to pick: M02047-1 is the only listed option. It is catalogued for human and rat reactivity, with a WB image from human placenta and THP-1 lysates at 1:500. Rat WB use needs separate verification.
Source: BosterBio F13A1 gene-info card — filtered to Western-blot-capable antibodies; each card shows that product's actual WB validation figure.
References
- UniProt Consortium. UniProt entry P00488.
- Human Protein Atlas. F13A1 tissue expression.
- PMC8125802 — target-verified WB comparison
- PMC8632253 — target-verified WB comparison
- PMC6950900 — target-verified WB comparison